| 000 | 01602 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516190708.0 | ||
| 264 | 0 | _c20140415 | |
| 008 | 201404s 0 0 eng d | ||
| 022 | _a1520-4804 | ||
| 024 | 7 |
_a10.1021/jm4012164 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCaglič, Dejan | |
| 245 | 0 | 0 |
_aIdentification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cFeb 2014 |
||
| 300 |
_a669-76 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBotulinum Toxins, Type A _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCatalytic Domain |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydrogen-Ion Concentration |
| 650 | 0 | 4 |
_aHydroxyquinolines _xchemical synthesis |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xmetabolism |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aSolubility |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aKrutein, Michelle C | |
| 700 | 1 | _aBompiani, Kristin M | |
| 700 | 1 | _aBarlow, Deborah J | |
| 700 | 1 | _aBenoni, Galit | |
| 700 | 1 | _aPelletier, Jeffrey C | |
| 700 | 1 | _aReitz, Allen B | |
| 700 | 1 | _aLairson, Luke L | |
| 700 | 1 | _aHouseknecht, Karen L | |
| 700 | 1 | _aSmith, Garry R | |
| 700 | 1 | _aDickerson, Tobin J | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 57 _gno. 3 _gp. 669-76 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm4012164 _zAvailable from publisher's website |
| 999 |
_c23414050 _d23414050 |
||